Metabolic Syndrome & Increased Parkinson’s Disease Risk

Date
Author
Parkinson's Foundation

All Science News articles summarize a research study and are not an official opinion, endorsement or position of the Parkinson’s Foundation’s.

Metabolic Syndrome (MetS) is a group of conditions that occur together that result in insulin resistance and increase the risk of heart disease, stroke and diabetes. According to a new study, MetS may be associated with Parkinson’s disease (PD).

While MetS can be prevented, controlled, treated and even reversed. It is not always easy to treat, since it is a cluster of five interrelated risk factors:

Category
Science News

Possible New Key to Parkinson’s Treatment

Date
Author
Parkinson's Foundation

All Science News articles summarize a research study and are not an official opinion, endorsement or position of the Parkinson’s Foundation’s.

In 10 percent of people with Parkinson's disease (PD), the disease is familial (tied to genetics), while the other 90 percent are nonfamilial. Mutations in the LRRK2 gene are the most common cause of familial PD. In fact, researchers have identified more than 100 LRRK2 gene mutations in families with PD. 

Category
Science News

“The Parkinson’s Pandemic: A Call to Action”

Date
Author
Parkinson's Foundation

All Science News articles summarize a research study and are not an official opinion, endorsement or position of the Parkinson’s Foundation’s.

JAMA Neurology, “Viewpoint”, 11/13/17

Authors: E. Ray Dorsey, MD, Department of Neurology, University of Rochester Medical Center, Rochester, NY; and Bastiaan R. Bloem, MD, PhD, Radboud University Medical Center, Department of Neurology, Nijmegen, the Netherlands.

Category
Science News

FDA Approves Extended-Release Amantadine (Gocovri) for Treatment of Dyskinesia

Date
Author
Parkinson's Foundation

All Science News articles summarize a research study and are not an official opinion, endorsement or position of the Parkinson’s Foundation’s.

The Parkinson’s Foundation alerts the community that extended-release amantadine capsules (GOCOVRI™) have been approved by the US Food and Drug Administration (FDA) for the treatment of dyskinesia in people with Parkinson's disease receiving levodopa-based therapy. This new approval was announced by the manufacturer on August 24.

Category
Science News

Brain MRI Tracks Parkinson’s Progression

Date
Author
Parkinson's Foundation

All Science News articles summarize a research study and are not an official opinion, endorsement or position of the Parkinson’s Foundation’s.

Researchers at a Parkinson’s Foundation Center of Excellence have found that a brain MRI (magnetic resonance imaging) that uses a special protocol can track changes that occur as Parkinson’s disease (PD) progresses. This biomarker could be used in clinical trials, as an objective way to monitor whether the therapies being tested are effective. The study appears in the August 2017 issue of Brain.

Category
Science News

mail icon

Subscribe here to get the latest news on treatments, research and other updates.